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Abstract
Background: The	lack	of	a	uniform	surveillance	case	definition	poses	a	challenge	to	
characterize	the	epidemiology,	clinical	features,	and	disease	burden	of	the	respira-
tory	syncytial	virus	(RSV).	Global	standards	for	RSV	surveillance	will	inform	immuni-
zation	policy	when	RSV	vaccines	become	available.
Methods: The	WHO	RSV	 surveillance	pilot	 leverages	 the	 capacities	of	 the	Global	
Influenza	Surveillance	and	Response	System	(GISRS).	Hospitalized	and	non‐hospital-
ized	medically	attended	patients	of	any	age	were	tested	for	RSV	using	standardized	
molecular	diagnostics	throughout	the	year	in	fourteen	countries.	An	extended	severe	
acute	 respiratory	 infection	 (extended	SARI)	or	an	acute	 respiratory	 infection	 (ARI)	
case	definition	was	used	that	did	not	require	fever	as	a	criterion.
Results: Amongst	 21	 221	 patients	 tested	 for	 RSV	 between	 January	 2017	 and	
September	2018,	15	428	(73%)	were	hospital	admissions.	Amongst	hospitalized	RSV‐
positive	patients,	50%	were	aged	<6	months	and	88%	<2	years.	The	percentage	of	
patients	testing	positive	for	RSV	was	37%	in	children	<6	months	and	25%	in	those	
aged	6	months	to	2	years.	Patients	with	fever	were	less	likely	to	be	RSV	positive	com-
pared	to	those	without	fever	(OR	0.74;	95%	CI:	0.63‐0.86).	For	infants	<6	months,	
29%	of	RSV	ARI	cases	did	not	have	fever.
Conclusion: Requiring	fever	in	a	case	definition	for	RSV	lowers	the	sensitivity	to	de-
tect	cases	in	young	children.	Countries	should	consider	ways	to	leverage	the	GISRS	
platform	to	implement	RSV	surveillance	with	an	augmented	case	definition	amongst	
the	young	pediatric	population.
K E Y W O R D S
case	definition,	respiratory	syncytial	virus,	surveillance
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1  | INTRODUC TION
Globally,	RSV	is	the	leading	infectious	cause	of	respiratory	morbidity	
and	mortality	in	children	aged	<5	years.	Annually,	there	are	an	esti-
mated	33	(uncertainty	range	21‐50)	million	episodes	of	RSV‐associ-
ated	acute	lower	respiratory	infection	(ALRI),	3.2	(uncertainty	range	
2.7‐3.8)	million	RSV	hospitalizations,	and	59	600	(uncertainty	range	
48	000‐74	500)	in‐hospital	RSV	deaths.1,2	RSV	vaccine	research	and	
development	efforts	have	progressed	significantly	 in	 recent	years,	
with	some	nineteen	vaccines	and	two	new	generation	monoclonal	
antibody	candidates	in	various	stages	of	clinical	trials.	It	is	possible	
that	a	maternal	RSV	vaccine	to	prevent	RSV	infection	in	young	in-
fants	may	be	licensed	in	the	next	few	years.3
Though	RSV	disease	occurs	across	all	ages,4-6	 it	disproportion-
ately	affects	children	<2	years.7	The	WHO	Strategic	Advisory	Group	
of	 Experts	 on	 Immunization	 (SAGE)	 has	 recommended	 improved	
case	definitions,	surveillance,	and	disease	estimates	for	RSV	espe-
cially	in	low‐	and	middle‐income	countries	where	the	burden	is	likely	
to	be	high.8	There	is	a	need	for	improved	RSV	surveillance	to	better	
understand	seasonality	and	disease	burden	in	different	countries.9 
RSV	surveillance	is	often	a	by‐product	of	influenza‐like	illness	(ILI)	or	
severe	acute	respiratory	infection	(SARI)	surveillance.10,11	However,	
these	case	definitions	require	a	history	of	fever	or	measured	fever	
and	 consequently	may	miss	 up	 to	 a	 significant	 proportion	 of	 RSV	
infections	especially	in	younger	children.12-14	In	2016,	WHO	piloted	
a	 RSV	 surveillance	 strategy	 that	 leverages	 the	 capacities	 of	 the	
Global	 Influenza	 Surveillance	 and	 Response	 System	 (GISRS)	 using	
a	broadened	case	definition.15	It	aimed	to	establish	laboratory	and	
epidemiological	standards	for	RSV	detection	to	improve	the	under-
standing	of	seasonality,	disease	burden,	and	age‐groups	at	highest	
risk.	Using	the	data	collected	in	this	pilot	study,	this	paper	aims	to	
describe	 the	 clinical	predictors	 for	RSV	presentation	and	evaluate	
the	performance	of	the	extended	SARI	and	ARI	case	definitions	for	
RSV	surveillance.
2  | METHODS
Surveillance	sites	from	fourteen	countries,	from	all	six	WHO	regions,	
participated	 in	 the	 pilot	 study.	 Countries	were	 selected	 based	 on	
having	a	WHO‐designated	National	 Influenza	Centre	and/or	a	na-
tional	public	health	 laboratory,	 a	 strong	national	 influenza	 surveil-
lance	system	and	an	interest	in	participation	in	the	pilot.	Countries	
were	required	to	test	1000	patients	annually	for	RSV	(250	patients	
in	each	of	the	four	age	groups—<6	months,	6	months	to	<5	years,	5	
to	<65	years,	and	65	years	and	more).
2.1 | Site profile and surveillance practices
In	 Argentina,	 Brazil,	 Chile,	 Egypt,	 Russian	 Federation,	 and	 South	
Africa,	 patients	 admitted	 to	 sentinel	 hospitals	 were	 screened	
across	all	ages,	whereas	 in	Australia	and	Canada	pediatric	hospital	
admissions	 only	 were	 screened.	 In	 Côte	 d'Ivoire,	 India,	 Mongolia,	
Mozambique,	and	Thailand,	patients	were	screened	across	all	ages	
in	 both	 sentinel	 hospitals	 and	 outpatient	 clinics.	 In	 the	 United	
Kingdom,	patients	were	screened	across	all	ages	attending	sentinel	
TA B L E  1  Sentinel	site	profile,	WHO	RSV	surveillance,	2017‐18
 
Age‐group under 
surveillance Patients under surveillance # sentinel sites
Start of 
surveillance
No. tested
(% hospitalized)
Argentina All	ages Inpatient 6 2016	wk52 1214	(99%)
Australia 0‐18	y Inpatient 1 2017	wk31 1560	(100%)
Brazil All	ages Inpatient 2 2017	wk03 727	(91%)
Canada 0-16 y Inpatient 12 2017	wk34 2178a	(100%)
Chile All	ages Inpatient 2 2017	wk01 883	(100%)
Côte	d'Ivoire All	ages Inpatient	+	Outpatient 9 2017	wk01 1772	(36%)
Egypt All	ages Inpatient 4 2017	wk01 1194	(100%)
India All	ages Inpatient	+	Outpatient 11 2017	wk01 1537	(82%)
Mongolia All	ages Inpatient	+	Outpatient 7 2017	wk02 1175	(89%)
Mozambique All	ages Inpatient	+	Outpatient 4 2017	wk01 969	(76%)
Russian	Federation All	ages Inpatient 18 2016	wk52 1648	(100%)
South	Africa All	ages Inpatient 5 2017	wk01 3409	(100%)
Thailand All	ages Inpatient	+	Outpatient 11 2017	wk01 2752	(53%)
United	Kingdomb Pediatric Inpatient 6 2017	wk39 2381c	(0%)
All	ages Outpatient 70	GPs
Abbreviations:	GP,	general	practitioners;	wk,	weeks;	y,	years.
aCanada	has	reported	data	for	laboratory‐confirmed	RSV‐positive	cases	only	from	11	of	its	12	sentinel	sites.	
bSurveillance	is	restricted	to	England	only.	
cThe	United	Kingdom	has	reported	case‐based	data	for	outpatient	surveillance	only.	
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General	Practitioner	clinics,	as	well	as	children	under	5	years	in	sen-
tinel	hospitals	 in	England	 (Table	1).	Canada	 reported	data	only	 for	
those	patients	who	tested	RSV	positive	and	was	excluded	from	the	
analysis.	The	number	and	type	of	sentinel	hospitals	(secondary	and	
tertiary‐level	 care)	 varied	across	 countries.	The	 selection	of	 senti-
nel	hospitals	and	clinics	was	largely	based	on	patient	load	and	con-
venience,	and	there	was	no	requirement	for	 them	to	be	nationally	
representative.
Physicians	and	nurses	screened	patients	admitted	the	previous	
day	with	acute	onset	cough	or	shortness	of	breath	or,	for	patients	
attending	outpatient	clinics,	with	at	least	one	of	cough,	sore	throat,	
shortness	 of	 breath,	 or	 runny	 nose.	 Sepsis	 and	 apnea	 were	 also	
criteria	 for	enrollment	 in	 infants	<6	months	 (Table	2).	Additionally,	
information	on	 fever,	wheeze,	 and	associated	 risk	 factors,	 such	as	
prematurity,	 malnutrition,	 cardiac	 and	 respiratory	 illness,	 and	 im-
munodeficiency,	 were	 recorded	 on	 a	 standardized	 case	 record	
form.	 The	 sampling	 strategy	 varied	 and	 ranged	 from	 screening	 of	
all	eligible	patients	to	screening	a	sample	of	eligible	patients	(eg,	on	
certain	days	of	the	week).	Patients	were	screened	all	year‐round	ex-
cept	in	Canada	and	England	where	patients	were	screened	between	
November	 and	 June.	 Age‐appropriate	 nasal,	 nasopharyngeal,	 or	
lower	respiratory	tract	specimens	were	collected	and	transported	in	
virus	transport	media	for	laboratory	RSV	testing.16	Specimens	from	
patients	with	reported	or	measured	fever	were	additionally	tested	
for	influenza	and	subtyped	using	standardized	rRT‐PCR	assays.17
2.2 | Laboratory testing
All	laboratories	participated	in	an	external	quality	assurance	program	
using	proficiency	panels	developed	by	the	Division	of	Viral	Diseases	
at	the	US	Centers	for	Disease	Control	and	Prevention	(CDC),	consist-
ing	 of	 contemporary	 and	 historical	 strains	 of	 RSV‐A	 and	 RSV‐B	 or	
panels	supplied	by	Quality	Control	for	Molecular	Diagnostics	(QCMD),	
United	Kingdom.	Specimens	received	by	laboratories	were	stored	at	
−70°C	and	batch	 tested	using	a	 standardized	 rRT‐PCR	assay	devel-
oped	by	CDC	for	generic	RSV	detection.	The	CDC	molecular	assay	
was	compatible	with	a	wide	range	of	virus	transport	media	and	differ-
ent	extraction	systems	and	PCR	amplification	platforms.	Primers	and	
probes	were	supplied	by	CDC,	and	extraction	reagent	kits	and	am-
plification	enzymes	were	supplied	by	International	Reagent	Resource	
(IRR)	of	CDC.	National	laboratories	had	the	option	to	use	commercial	
or	 in‐house	 laboratory	developed	 tests	 (LDTs)	provided	 these	were	
validated	 against	 the	 CDC	 RSV	 assay.	 The	 US	 CDC,	 Public	 Health	
England,	Colindale,	and	National	Institute	of	Communicable	Diseases,	
Johannesburg	provided	training	and	quality	assurance	support,	as	re-
quired,	 to	all	participating	national	 laboratories.	The	WHO	FluMart	
data	platform	was	adapted	 to	 receive	 case‐based	 clinical	 and	 labo-
ratory	RSV	data,	and	countries	were	required	to	upload	anonymized	
RSV	surveillance	data	every	week	or	every	fortnight.	Public	access	to	
an	 interactive	 aggregated	RSV	 surveillance	output	was	provided	 at	
http://ais.paho.org/phip/viz/ed_who_rsv.asp.
2.3 | Data analysis
Data	from	Canada	were	excluded	for	analysis	as	they	had	reported	
only	on	RSV‐positive	cases.	The	start	of	surveillance	varied	(range	
epidemiological	week	 (EW)	 52	 of	 2016	 to	 EW	39	of	 2017)	with	
11	 of	 14	 countries	 initiating	 surveillance	 in	 the	 first	 quarter	 of	
2017.	 The	 end	date	 for	 this	 analysis	was	 set	 at	 EW	39	of	 2018.	
England	 reported	data	only	 from	 their	General	Practitioner	 sen-
tinel	surveillance	(Table	1).	All	analyses	were	done	separately	for	
inpatient	 and	 outpatient	 surveillance	 and	 disaggregated	 into	 six	
age‐groups—<6	months,	 6	months	 to	 <2	 years,	 2	 to	 <5	 years,	 5	
to	<18	years,	18	to	<65	years,	and	65	years	and	more.	Univariate	
TA B L E  2  Surveillance	case	definitions	for	RSV,	2017‐18
 RSV Influenza
In	patient Extended	SARI
•	 Severe	(overnight	hospitalization)
•	 Acute	(onset	within	past	10	d)
•	 Respiratory	infection	(cough	or	shortness	of	breath)
In	infants	<6	mo	age
• Apneaa
•	 Sepsis
•	 Fever	more	than	37.5°C	or	hypothermia
•	 Shockb
•	 Seriously	ill	without	apparent	cause
SARI
•	 Severe	(overnight	hospitalization)
•	 Acute	(onset	within	past	10	d)
•	 History	of	fever	or	measured	fever	of	38°C	
or more
•	 Respiratory	infection	(cough	or	shortness	of	
breath)
Out	patient ARI
•	 Acute	(onset	within	past	10	d)
•	 Respiratory	infection	(at	least	one	of	cough,	sore	throat,	shortness	of	
breath	or	runny	nose)
Extended	ILI
•	 Acute	(onset	within	past	10	d)
•	 Respiratory	infection	(cough)
ILI
•	 Onset	within	past	10	d
•	 Measured	fever	of	38°C	or	more,	and
•	 Cough
Abbreviations:	ARI,	acute	respiratory	infection;	ILI,	influenza‐like	illness;	RSV,	respiratory	syncytial	virus;	SARI,	severe	acute	respiratory	infection.
aApnea	defined	as	temporary	cessation	of	breathing	from	any	cause.	
bShock	defined	as	lethargy,	fast	breathing,	cold	skin,	prolonged	capillary	refill	or	weak	pulse.	
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logistic	 regression	was	 used	 to	 determine	 clinical	 predictors	 for	
RSV	 cases.	 The	 SARI	 and	 ILI	 case	 definitions	 were	 evaluated	
against	the	extended	SARI	and	ARI	definitions	that	did	not	require	
fever.	The	relative	sensitivity	was	estimated	as	it	was	not	known	
how	many	RSV	cases	were	missed	who	did	not	 fit	 the	extended	
SARI	or	ARI	case	definitions.	The	positive	predictive	value	(PPV)	
was	 calculated	 for	 the	 age‐specific	 percent	 positivity	 cumulated	
over	 the	 study	 period.	We	 also	 evaluated	 the	 individual	 perfor-
mance	 of	 apnea	 and	 sepsis	 (for	 infants	 <6	 months),	 and	 when	
wheezing	 (clinical	 presentation	 of	 RSV‐associated	 bronchiolitis)	
was	added	to	the	extended	SARI	case	definition.	The	area	under	
the	curve	(AUC)	was	estimated	as	a	measure	of	accuracy	of	how	
well	an	alternate	case	definition	separates	the	group	being	tested	
into	those	with	and	without	the	disease	as	determined	by	the	ex-
isting	reference	case	definition.	An	AUC	(range	0‐1)	<0.7	indicates	
a	poor	discriminatory	ability	of	the	alternate	case	definition	in	re-
lation	to	the	reference	case	definition.	All	analysis	was	done	with	
Stata	v15	software.
3  | RESULTS
A	total	of	21	221	patients	(excluding	Canada)	were	tested	for	RSV	
of	whom	15	428	 (73%)	were	 inpatients	 (Table	1).	Overall,	 60%	of	
patients	tested	were	aged	<5	years	(20%	<6	months,	30%	between	
6	months	to	2	years	and	10%	between	2	and	5	years).	The	age	distri-
bution	of	patients	tested	varied	by	country	(Figure	1).	Overall,	<10%	
of	patients	tested	were	aged	65	years	or	older	 (Table	3).	Amongst	
inpatients,	a	total	of	2963	(19.2%)	tested	positive	for	RSV.	Amongst	
RSV‐positive	hospitalized	patients,	2598	(87.6%)	were	<2	years	age,	
and	1461	(49.3%)	were	<6	months.	The	percentage	testing	positive	
for	RSV	was	similar	in	males	and	females.
3.1 | Clinical characteristics
Amongst	hospitalized	patients,	RSV	percent	positivity	was	high-
est	 (37%)	 in	 infants	 <6	 months,	 25%	 in	 children	 6	 months	 to	
2	years,	and	12%	in	children	2‐5	years	age.	RSV	percent	positiv-
ity	was	 about	 4%	 in	 adults	 and	older	 adults	 aged	65	 years	 and	
more.	RSV	percent	positivity	was	 lower	but	showed	similar	age	
trends	 amongst	 non‐hospitalized	 patients.	 In	 contrast,	 percent	
positivity	for	influenza	amongst	hospitalized	patients	was	3%‐7%	
in	 children	 <2	 years,	 11%	 in	 adults	 aged	 18	 to	 <65	 years,	 and	
14%	in	older	adults	aged	over	65	years	(Figure	2).	The	age‐group	
stratified	 RSV	 percent	 positivity	 varied	 across	 countries.	 RSV	
predominated	over	influenza	in	children	<2	years	age	(especially	
infants	<6	months)	whereas	the	reverse	was	seen	in	older	adults	
aged	65	years	and	more.	This	trend	was	seen	for	both	hospital-
ized	 and	 non‐hospitalized	 patients	 across	 all	 the	 participating	
countries	(Figure	3).
Amongst	 hospitalized	 patients	 <6	 months,	 apnea	 was	 signifi-
cantly	 more	 prevalent	 amongst	 RSV‐positive	 infants	 (8.3%)	 than	
those	 who	 tested	 negative	 (6.0%)	 (odds	 ratio	 (OR)	 1.42;	 95%	 CI:	
1.05‐1.94)	 (Table	 4).	 Sepsis	 was	 less	 common	 amongst	 RSV‐posi-
tive	infants	(4.7%)	than	those	who	tested	negative	(10%)	(OR	‐	0.44;	
95%	CI:	0.31‐0.64).	Cough	(OR:	6.21,	95%	CI:	4.77‐8.08),	shortness	
of	 breath	 (OR:	1.64,	95%	CI:	 1.38‐1.96),	wheezing	 (OR:	1.73,	95%	
CI:	1.49‐2.01),	runny	nose	(OR:	1.75,	95%	CI:	1.50‐2.04),	and	lower	
chest	in‐drawing	(OR:	2.46,	95%	CI:	2.07‐2.91)	were	all	significantly	
more	common	in	RSV‐infected	infants.	The	findings	were	similar	for	
hospitalized	children	aged	6	months	to	2	years,	though	the	associa-
tion	with	wheeze	was	not	significant.
The	presence	of	either	reported	or	measured	fever	was	signifi-
cantly	 less	 likely	 amongst	 RSV	 cases	 than	 RSV‐negative	 children	
<2	years	than	in	those	aged	6	months	to	2	years.	Similar	trends	 in	
clinical	 predictors	 were	 seen	 in	 older	 children,	 adults,	 and	 older	
adults	but	were	generally	not	statistically	significant.	Presence	of	a	
pre‐existing	illness	was	not	significantly	associated	with	RSV	infec-
tion	except	in	children	aged	5‐18	years.	Clear	statistically	significant	
trends	 for	 RSV	 infection	 for	most	 clinical	 predictors	 could	 not	 be	
ascertained	for	patients	for	any	of	the	age‐groups	attending	outpa-
tient	clinics	in	a	primary	care	setting,	but	these	analyses	were	based	
on	smaller	numbers	of	patients	and	the	confidence	intervals	on	odds	
ratio	estimates	were	generally	wide.
F I G U R E  1  Age	distribution	of	
specimens	tested,	WHO	RSV	surveillance,	
2017‐18
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3.2 | Case definition
Amongst	 hospitalized	 infants	 <6	 months	 age,	 29%	 of	 those	 RSV	
cases	that	otherwise	had	been	captured	by	an	extended	SARI	case	
definition	 were	 missed	 after	 inclusion	 of	 measured	 or	 reported	
fever.	The	positive	predictive	value	 (PPV)	of	 the	SARI	case	defini-
tion	that	included	fever	was	34%	for	infants	<6	months	and	24%	for	
children	between	6	months	to	<2	years.	The	ability	of	fever	to	cor-
rectly	 identify	the	presence	or	absence	of	RSV	infection	was	poor	
(area	under	the	curve	(AUC)	–	0.31).	The	percent	of	missed	cases	was	
lower	(18‐20%)	in	children	6	months	to	<5	years	age.	Apnea	and	sep-
sis	individually	had	low	sensitivity	(8.3%	and	4.7%)	but	were	highly	
specific	(93%	and	89%)	for	RSV	infection	in	infants	<6	months.	The	
addition	of	wheeze	 to	 the	 extended	SARI	 case	definition	 reduced	
the	sensitivity	to	36%	in	hospitalized	infants	<6	months	age	and	to	
about	32‐33%	in	children	aged	6	months	to	5	years.	Similar	trends	
were	seen	amongst	non‐hospitalized	children,	albeit	with	lower	cer-
tainty.	Amongst	hospitalized	older	adults	aged	65	years	and	more,	
the	 sensitivity	 of	 the	 SARI	 case	 definition	 after	 inclusion	 of	 fever	
and	wheeze	was	78%	and	40%,	 respectively.	Amongst	non‐hospi-
talized	older	adults	aged	65	years	and	more,	 the	addition	of	 fever	
reduced	the	sensitivity	to	27%.	However,	the	addition	of	wheeze	to	
the	extended	SARI	case	definition	increased	the	sensitivity	to	98%,	
respectively	(Table	5).
4  | DISCUSSION
The	 lack	 of	 a	 global	 uniform	 surveillance	 case	 definition	 for	 RSV	
complicates	the	interpretation	of	surveillance	data.	In	the	WHO	RSV	
surveillance	pilot,	the	use	of	an	extended	SARI	or	an	ARI	case	defini-
tion	substantially	increased	the	number	of	RSV	infections	detected	
also	seen	in	other	studies.12,13	These	definitions	do	not	require	fever	
to	identify	a	suspect	case.	On	the	other	hand,	the	inclusion	of	fever	
in	the	RSV	surveillance	case	definition	may	not	matter	if	the	objec-
tive	is	solely	to	ascertain	onset	of	the	RSV	season.	However,	includ-
ing	fever	may	significantly	compromise	the	use	of	surveillance	data	
to	estimate	RSV	disease	burden.
TA B L E  3  Age,	sex	distribution	of	patients,	and	RSV	detection,	2017‐18
 
Inpatient surveillance
Tested
n (%)
Outpatient surveillance
Tested
n (%)
RSV negative
n (%)
RSV positive
n (%)
RSV negative
n (%)
RSV positive
n (%)
Age
0	to	<6	m 2493	(20.5) 1461	(49.3) 3954	(26.2) 157	(3.3) 40	(9.9) 197	(3.9)
6	m	to	<2	y 3456	(28.5) 1137	(38.3) 4593	(30.4) 726	(15.6) 157	(38.9) 883	(17.5)
2	to	<5	y 1365	(11.2) 187	(6.3) 1552	(10.3) 579	(12.5) 93	(23.0) 672	(13.3)
5	to	<18	y 1077	(8.8) 49	(1.6) 1126	(7.4) 768	(16.6) 19	(4.7) 787	(15.6)
18	to	<65	y 2546	(21.0) 74	(2.5) 2620	(17.3) 1991	(43.0) 74	(18.8) 2065	(41.0)
65+	y 1175	(9.7) 55	(1.8) 1230	(8.1) 405	(8.7) 20	(4.9) 425	(8.4)
Male 6255	(53.3) 1565	(53.9) 7820	(53.4) 1241	(52.7) 160	(57.5) 1401	(53.2)
F I G U R E  2  Age	distribution	and	
percent	positivity	of	RSV	and	influenza,	
2017‐18
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F I G U R E  3  A,	RSV	and	influenza	proportion	positive	(inpatient	surveillance),	2017‐18.	B,	RSV	and	influenza	proportion	positive	
(outpatient	surveillance),	2017‐18
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TA B L E  4  Clinical	predictors	for	laboratory‐confirmed	RSV	for	patients	with	extended	SARI	and	ARI	case	definition,	2017‐18
 
Inpatient surveillance
Univariate
Odds ratio (95% CI)
Outpatient surveillance
Univariate
Odds ratio (95% CI)
RSV negative
n (%)
RSV positive
n (%)
RSV negative
n (%)
RSV positive
n (%)
Young	infants	(0	to	<6	m)
Apnea 103	(6.0) 75	(8.3) 1.42	(1.05‐1.94) 0	(0) 0	(0) –
Sepsis 166	(10.0) 37	(4.7) 0.44	(0.31‐0.64) 0	(0) 0	(0) –
Cough 1813	(76.3) 1343	(95.2) 6.21	(4.77‐8.08) 147	(93.6) 37	(92.5) 0.83	(0.21‐3.20)
Shortness	of	breath 643	(49.3) 531	(61.6) 1.64	(1.38‐1.96) 17	(11.2) 9	(28.1) 3.08	(1.22‐7.74)
Fever	(history) 1044	(53.4) 503	(45.9) 0.74	(0.63‐0.86) 127	(81.9) 26	(76.4) 0.71	(0.29‐1.74)
Fever	(≥38°C) 1718	(76.8) 847	(68.8) 0.66	(0.57‐0.77) 19	(38.7) 4	(80.0) 6.31	(0.65‐60.8)
Wheeze 669	(32.0) 527	(45.0) 1.73	(1.49‐2.01) 2	(1.5) 3	(10) 6.94	(1.10‐43.5)
Runny	nose 856	(44.1) 590	(58.0) 1.75	(1.50‐2.04) 2	(5.8) 2	(66.6) 32.0	(1.95‐522.7)
Lower	chest	in‐drawing 717	(41.5) 525	(63.6) 2.46	(2.07‐2.91) 0	(0) 1	(50) –
Pre‐existing	conditiona 453	(18.1) 190	(7.9) 0.67	(0.56‐0.80) 6	(4.0) 0	(0) –
Children	(6	m	to	<2	y)
Cough 3170	(93.5) 1066	(96.5) 1.92	(1.35‐2.74) 656	(91.2) 140	(90.3) 0.89	(0.49‐1.62)
Shortness	of	breath 1483	(57.9) 565	(65.7) 1.39	(1.18‐1.63) 92	(13.8) 27	(20.3) 1.58	(0.98‐2.55)
Fever	(history) 1858	(65.6) 597	(61.7) 0.84	(0.72‐0.98) 583	(82.3) 126	(82.3) 1.00	(0.63‐1.58)
Fever	(≥38°C) 2188	(71.6) 691	(69.3) 0.89	(0.76‐1.04) 162	(54.9) 37	(77.0) 2.76	(1.35‐5.62)
Wheeze 1102	(38.7) 384	(41.1) 1.10	(0.94‐1.28) 38	(6.6) 14	(10.6) 1.67	(0.87‐3.18)
Sore	throat 629	(27.6) 218	(32.2) 1.24	(1.03‐1.49) 101	(15.7) 21	(16.9) 1.09	(0.65‐1.82)
Runny	nose 1167	(49.4) 472	(61.3) 1.61	(1.36‐1.90) 22	(13.9) 3	(21.4) 1.68	(0.43‐6.52)
Lower	chest	in‐drawing 904	(42.4) 343	(56.4) 1.75	(1.46‐2.10) 6	(9.0) 3	(30.0) 4.28	(0.87‐21.0)
Pre‐existing	conditiona 590	(17.0) 183	(9.5) 0.93	(0.77‐1.11) 17	(2.6) 6	(4.8) 1.86	(0.72‐4.83)
Children	(2	to	<5	y)
Cough 1250	(92.8) 172	(93.4) 1.10	(0.59‐2.04) 542	(95.0) 86	(96.6) 1.48	(0.44‐4.97)
Shortness	of	breath 586	(54.3) 90	(54.2) 0.99	(0.71‐1.38) 57	(12.0) 14	(19.4) 1.75	(0.92‐3.35)
Fever	(history) 736	(64.7) 98	(60.4) 0.83	(0.59‐1.16) 459	(81.2) 77	(83.7) 1.18	(0.65‐2.14)
Fever	(≥38°C) 940	(75.5) 121	(71.6) 0.81	(0.57‐1.17) 182	(70.5) 36	(85.7) 2.50	(1.01‐6.19)
Wheeze 386	(34.0) 60	(36.5) 1.11	(0.79‐1.56) 33	(7.8) 10	(14.0) 1.92	(0.90‐4.09)
Sore	throat 303	(31.8) 43	(34.9) 1.15	(0.77‐1.70) 123	(27.1) 25	(39.6) 1.76	(1.02‐3.04)
Runny	nose 414	(48.3) 60	(50.8) 1.10	(0.75‐1.62) 16	(14.2) 2	(28.5) 2.40	(0.42‐13.4)
Lower	chest	in‐drawing 277	(36.8) 47	(45.6) 1.43	(0.95‐2.17) 8	(13.7) 0	(0) –
Pre‐existing	conditiona 305	(22.3) 33	(9.5) 0.74	(0.50‐1.10) 23	(5.0) 3	(4.7) 0.93	(0.27‐3.20)
Children	(5	to	<18	y)
Cough 929	(86.7) 45	(91.8) 1.71	(0.60‐4.85) 693	(96.1) 16	(84.2) 0.21	(0.05‐0.78)
Shortness	of	breath 471	(44.3) 24	(48.9) 1.20	(0.67‐2.13) 87	(17.1) 4	(30.7) 2.14	(0.64‐7.10)
Fever	(history) 600	(66.0) 21	(45.6) 0.43	(0.23‐0.78) 635	(85.4) 17	(89.4) 1.44	(0.32‐6.34)
Fever	(≥38°C) 669	(69.6) 27	(62.7) 0.73	(0.39‐1.38) 237	(77.2) 4	(100.0) –
Wheeze 178	(18.9) 9	(19.5) 1.04	(0.49‐2.19) 30	(6.9) 1	(8.3) 1.20	(0.15‐9.68)
Sore	throat 350	(37.6) 8	(23.5) 0.50	(0.22‐1.13) 218	(48.0) 2	(18.1) 0.24	(0.05‐1.12)
Runny	nose 197	(36.4) 15	(57.6) 2.38	(1.07‐5.28) 21	(16.6) 0	(0) –
Lower	chest	in‐drawing 95	(22.8) 13	(52.0) 3.66	(1.61‐8.28) 0	(0) 1	(100) –
Pre‐existing	conditiona 158	(14.6) 13	(8.6) 2.10	(1.08‐4.04) 21	(4.6) 1	(9.0) 2.06	(0.25‐16.8)
Adults	(18	to	<65	y)
Cough 2326	(92.3) 71	(95.9) 1.95	(0.60‐6.26) 1746	(96.2) 64	(94.1) 0.63	(0.22‐1.78)
(Continues)
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Surveillance	 confirmed	 the	 high	 burden	 of	 RSV	 in	 children	
<2	 years,	 especially	 in	 infants	 <6	 months.7,18‐20	 RSV	 commonly	
manifests	 clinically	 in	 infants	 with	 bronchiolitis.21-23	 Wheeze	 has	
been	one	of	 the	clinical	end	points	of	 interest	 to	evaluate	vaccine	
efficacy	 trials.24	 From	 a	 surveillance	 case	 definition	 perspective,	
including	wheeze	 as	 a	 criteria	 reduces	 its	 sensitivity	 in	 children.25 
Apnea,	 though	 it	 lacked	 sensitivity,	 was	 a	 significant	 clinical	 pre-
dictor	 for	 severe	RSV	 infection	 requiring	hospitalization	 in	 infants	
<6	months.22,26‐28	The	reason	for	sepsis	to	be	significantly	less	com-
mon	amongst	RSV‐positive	hospitalized	young	infants	in	this	study	
in	contrast	to	other	studies	29,30	is	unclear.
The	RSV	surveillance	case	definition	 is	not	 intended	to	modify	
or	replace	the	SARI	or	ILI	case	definition	for	influenza	surveillance.	
Countries	 reported	 challenges	 in	 the	 adoption	 of	 the	 extended	
SARI	 case	 definition	 in	 the	 early	 stages	 of	 the	 RSV	 surveillance	
which	 were	 resolved	 through	 training.	 In	 practice,	 the	 physician	
or	nurse	 in	a	 sentinel	hospital	 engaged	 in	both	RSV	and	 influenza	
surveillance,	 screened	 patients	 with	 acute	 onset	 cough	 or	 short-
ness	of	breath,	and	collected	an	appropriate	respiratory	specimen.	
Information	on	 the	presence	or	 absence	of	 fever	was	 recorded	 in	
the	 specimen	 requisition	 form	 and	 sent	 to	 the	 laboratory	 along	
with	the	respiratory	specimen.	At	the	laboratory,	all	the	specimens	
were	tested	for	RSV,	whereas	those	specimens	from	patients	with	
fever	were	additionally	 tested	 for	 influenza.	Moreover,	 the	 results	
for	 influenza	were	reported	to	FluNet	only	for	those	patients	with	
fever.	Notwithstanding	the	additional	burden	of	reporting,	this	en-
sured	 that	 the	RSV	 surveillance	 did	 not	 disturb	 the	 influenza	 sur-
veillance	 system	 but	 complemented	 it	 by	 targeting	 a	 very	 young	
age‐group	that	is	important,	yet	often	underrepresented	in	influenza	
surveillance.
The	 WHO	 RSV	 surveillance	 pilot	 had	 several	 limitations,	
and	 its	early	findings	need	to	be	 interpreted	with	some	caveats.	
Generalization	of	the	findings	should	be	made	with	caution.	First,	
the	 number,	 type,	 and	 selection	 of	 sentinel	 sites	 varied	 across	
countries	and	were	generally	not	designed	to	be	nationally	repre-
sentative	or	comparable	in	terms	of	the	clinical	severity	of	patients	
included.	 Second,	 the	 strategy	 for	 sampling	 patients	 for	 testing	
varied	across	sentinel	sites.	This	would	need	to	be	accounted	for	
when	estimating	disease	burden	from	surveillance	data	but	 is	of	
no	 consequence	 for	 this	 analysis.	 Third,	 Brazil	 faced	 a	 shortfall	
of	extended	SARI	cases	and	had	to	bridge	the	gap	with	patients	
sourced	from	SARI	surveillance.	However,	with	over	20	000	pa-
tients	 from	 all	 countries	 pooled	 together,	 the	 bias	 in	 evaluating	
the	performance	of	fever	as	a	criterion	for	detecting	RSV	would	
be	 small.	 Fourth,	 the	 PPV	 is	 likely	 to	 be	 higher	 during	 the	 RSV	
season,	but	 it	was	beyond	 the	scope	of	 this	analysis	 to	 robustly	
determine	 country‐specific	 seasonality	 patterns	 from	 data	 that	
covered	just	2	years.
 
Inpatient surveillance
Univariate
Odds ratio (95% CI)
Outpatient surveillance
Univariate
Odds ratio (95% CI)
RSV negative
n (%)
RSV positive
n (%)
RSV negative
n (%)
RSV positive
n (%)
Shortness	of	breath 1351	(53.8) 39	(54.1) 1.01	(0.63‐1.62) 572	(50.6) 21	(41.1) 0.68	(0.38‐1.20)
Fever	(history) 1493	(84.4) 43	(79.6) 0.72	(0.36‐1.41) 1592	(88.8) 53	(80.3) 0.51	(0.27‐0.95)
Fever	(≥38°C) 2051	(94.3) 47	(85.4) 0.35	(0.16‐0.76) 353	(83.2) 20	(83.3) 1.00	(0.33‐3.03)
Wheeze 432	(17.8) 9	(12.5) 0.65	(0.32‐1.33) 184	(22.8) 7	(16.6) 0.67	(0.29‐1.54)
Sore	throat 799	(41.7) 20	(35.0) 0.75	(0.43‐1.31) 387	(61.4) 17	(48.5) 0.59	(0.29‐1.17)
Runny	nose 388	(40.6) 10	(52.6) 1.62	(0.65‐4.02) 43	(29.0) 2	(28.5) 0.97	(0.18‐5.22)
Lower	chest	in‐drawing 70	(12.1) 2	(28.5) 2.90	(0.55‐15.2) 0	(0) 1	(16.6) –
Pregnant 148	(9.0) 1	(2.3) 0.23	(0.03‐1.75) 12	(2.5) 2	(8.0) 3.34	(0.70‐15.8)
Pre‐existing	conditionb 860	(33.7) 31	(41.8) 1.41	(0.88‐2.25) 61	(9.5) 3	(8.3) 0.86	(0.25‐2.89)
Older	adults	(65+	y)
Cough 1065	(92.1) 51	(92.7) 1.08	(0.38‐3.08) 359	(97.8) 17	(94.4) 0.37	(0.04‐3.20)
Shortness	of	breath 763	(66.1) 39	(70.9) 1.24	(0.68‐2.25) 146	(74.4) 9	(75.0) 1.02	(0.26‐3.94)
Fever	(history) 423	(62.2) 24	(58.5) 0.85	(0.45‐1.62) 308	(94.4) 16	(100) –
Fever	(≥38°C) 896	(83.8) 36	(75.0) 0.57	(0.29‐1.13) 34	(82.9) 0	(0) –
Wheeze 298	(27.2) 22	(40.0) 1.78	(1.02‐3.10) 54	(47.7) 2	(40.0) 0.72	(0.11‐4.52)
Sore	throat 242	(29.9) 10	(24.3) 0.75	(0.36‐1.56) 35	(58.3) 1	(33.3) 0.35	(0.03‐4.15)
Runny	nose 107	(38.6) 7	(36.8) 0.92	(0.35‐2.42) 7	(36.8) 0	(0) –
Lower	chest	in‐drawing 62	(19.8) 6	(30.0) 1.72	(0.63‐4.67) 0	(0) 0	(0) –
Pre‐existing	conditionb 762	(64.8) 37	(67.2) 1.11	(0.62‐1.98) 21	(31.8) 1	(33.3) 1.07	(0.09‐12.4)
aPre‐existing	condition	includes	prematurity,	chronic	respiratory	disease	including	asthma,	malnutrition,	or	immunodeficiency.	
bPre‐existing	condition	includes	respiratory	disease,	diabetes,	heart	disease,	or	immunodeficiency.	
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There	were	several	factors	that	could	cause	potential	bias	in	the	
study.	The	clinical	data	were	collected	from	patients	or	caregivers	
or	physician	records	and	could	be	subject	to	recall	or	measurement	
bias.	It	was	beyond	the	scope	of	this	analysis	to	evaluate	the	influ-
ence	of	recall	of	symptoms	based	on	the	interval	between	the	onset	
of	symptoms	and	when	patients	presented	at	the	hospital	or	clinic.	
On	the	other	hand,	recall	bias	 is	not	expected	to	be	related	to	the	
RSV	infection	status.	The	health	infrastructure,	and	healthcare	avail-
ability,	affordability	and	accessibility	varied	across	different	country	
contexts.	The	health	seeking	behavior	of	populations	is	likely	to	vary	
across	different	cultural	contexts.	The	hospital	admission	practices	
are	likely	to	vary	across	different	settings	as	indicated	by	the	hetero-
geneity	 in	the	severity	of	 illness	of	patients	screened	for	RSV	also	
varied	across	different	sites.	It	is	beyond	the	scope,	and	not	the	pur-
pose,	of	the	RSV	or	any	routine	national	disease	surveillance	system	
to	collect	information	on	these	variables	which	are	better	studied	in	
specialized	research	settings.
In	conclusion,	we	found	that	pilot	countries	with	existing	influ-
enza	surveillance	were	able	to	build	on	RSV	surveillance	on	top	of	
their	influenza	surveillance	program	with	marginal	incremental	costs	
and	effort.	Countries	did	not	report	any	significant	adverse	impact	
on	influenza	surveillance.	The	inclusion	of	fever	as	a	criterion	sub-
stantially	reduces	the	sensitivity	of	a	case	definition	to	detect	RSV	
infection	in	young	children,	where	the	burden	of	RSV	is	the	highest.	
WHO	should	continue	to	closely	monitor	for	adverse	impact,	if	any,	
on	influenza	surveillance	in	different	settings.
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TA B L E  5  Performance	of	SARI	and	ILI	case	definitions	with	reference	to	extended	SARI	(inpatient	surveillance)	and	ARI	(outpatient	
surveillance),	2017‐18
 
Inpatient surveillance
PPV
(95% CI) AUC
Outpatient surveillance
PPV
(95% CI) AUC
Sensitivity
(95% CI)
Specificity
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
Young	infants	(0	to	<6	m) Percent	positivity	–	36.9% Percent	positivity	–	15.8%
SARI	(inpatient)/ILI	
(outpatient)
71%	(69‐73) 20%	(18	−21) 34%	(32‐36) 0.31 71%	(51‐86) 15%	(10‐22) 13%	(8‐20) 0.43
Apnea 8.3%	(6‐10) 93%	(92‐95) 42%	(34‐49) 0.51 – – –  
Sepsis 4.7%	(3‐6) 89%	(88‐91) 18%	(13‐24) 0.47 – – –  
Ex‐SARI/ARI	+	wheeze 36%	(33‐38) 73%	(71‐74) 44%	(41‐46) 0.47 0%	(2‐12) 98%	(95‐99) – 0.49
Children	(6	m	to	<2	y) Percent	positivity	–	24.7% Percent	positivity	–	16.1%
SARI	(inpatient)/ILI	
(outpatient)
82%	(80‐84) 16%	(15‐17) 24%	(23‐26) 0.32 83%	(76‐89) 11%	(8‐13) 15%	(12‐18) 0.47
Ex‐SARI/ARI	+	wheeze 33%	(31‐36) 68%	(66‐69) 25%	(23‐28) 0.44 1.6%	(0.2‐6) 97%	(96‐98) 12%	(2‐39) 0.49
Children	(2	to	<5	y) Percent	positivity	–	12.0% Percent	positivity	−12.2%
SARI	(inpatient)/ILI	
(outpatient)
80%	(74‐85) 16%	(14‐18) 11%	(9‐13) 0.29 92%	(82‐97) 9.9%	(7‐13) 12%	(9‐15) 0.51
Ex‐SARI/ARI	+	wheeze 32%	(25‐39) 71%	(69‐74) 13%	(10‐17) 0.44 0%	(0‐6) 97%	(95‐98) – 0.48
Children	(5	to	<18	y) Percent	positivity	–	4.3% Percent	positivity	–	2.3%
SARI	(inpatient)/ILI	
(outpatient)
77%	(63‐87) 18%	(15‐20) 4%	(2‐5) 0.21 81%	(48‐97) 8.3%	(6‐11) 2%	(1‐4) 0.45
Ex‐SARI/ARI	+	wheeze 18%	(9‐32) 83%	(81‐85) 4%	(2‐9) 0.44 0%	(0‐28) 99%	(98‐100) – 0.49
Adults	(18	to	<65	y) Percent	positivity	–	2.8% Percent	positivity	–	5.3%
SARI	(inpatient)/ILI	
(outpatient)
89%	(79‐94) 6.6%	(5‐7) 2%	(2‐3) 0.47 86%	(70‐95) 16%	(13‐19) 5%	(3‐7) 0.51
Ex‐SARI/ARI	+	wheeze 12%	(6‐22) 83%	(81‐84) 2%	(0.9‐4) 0.47 2.7%	(0.1‐14) 98%	(97‐99) 9%	(0.4‐42) 0.50
Older	adults	(65+	y) Percent	positivity	–	4.4% Percent	positivity	–	4.3%
SARI	(inpatient)/ILI	
(outpatient)
78%	(64‐87) 15%	(13‐17) 4%	(3‐5) 0.46 66%	(9‐99) 27%	(17‐39) 4%	(0.6‐14) 0.46
Ex‐SARI/ARI	+	wheeze 40%	(27‐54) 74%	(72‐77) 6%	(4‐10) 0.57 0%	(0‐70) 98%	(91‐99) – 0.49
Abbreviations:	ARI,	acute	respiratory	infection;	AUC,	area	under	curve;	CI,	confidence	interval;	Ex‐SARI,	extended	severe	acute	respiratory	infection;	
ILI,	influenza‐like	illness;	PPV,	positive	predictive	value;	SARI,	severe	acute	respiratory	infection.
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